Feasibility of externalized peritoneovenous shunt (EPVS) for malignant ascites by Tokue, Hiroyuki et al.
RESEARCH Open Access
Feasibility of externalized peritoneovenous
shunt (EPVS) for malignant ascites
Hiroyuki Tokue
1,2*, Yoshito Takeuchi
2, Yasuaki Arai
2, Keitaro Sofue
2, Noriaki Sakamoto
2, Yoshito Tsushima
1 and
Keigo Endo
1
Abstract
Purpose: To evaluate a new modified peritoneovenous shunt therapy, the externalized peritoneovenous shunt
(EPVS) system placement, used to treat patients with malignant ascites.
Methods: We retrospectively reviewed 10 patients, who were not suited for conventional peritoneovenous shunts
(PVS), with malignant ascites, which was refractory to medical therapies. Patient characteristics, technical success,
efficacy, duration of EPVS placement, adverse events, and outcome were evaluated. Clinical efficacy of the EPVS
was evaluated by the change in subjective symptoms.
Results: The primary reasons for applying EPVS were severe anasarca in 4 patients, potential PVS dysfunction in 3
patients, poor performance status in 2 patients, and a history of PVS occlusion in 1 patient. EPVS was successfully
placed in all patients, and it provided clinical efficacy in 8 patients (80%). Early death occurred within 7 days after
EPVS placement in 2 patients because of renal failure. The median duration of EPVS placement was 10.4 days
(range, 2-28 days). In 6 patients (60%), the EPVS was exchanged to conventional PVS sequentially, since the initial
EPVS placement resulted in an improvement of the subjective symptoms of the patients, without serious
complications.
Conclusion: EPVS placement may be an option for patients with malignant ascites who may not be appropriate
for conventional PVS placement.
Keywords: Denver shunt, peritoneovenous shunt (PVS), externalized peritoneovenous shunt (EPVS), malignant
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Background
A peritoneovenous shunt (PVS), which is also known as
a Denver shunt, may be effective for palliating symp-
toms in patients with malignant ascites, which contri-
bute to a deterioration of the patient’s quality of life
(QOL) and which are refractory to conservative nonsur-
gical therapies. Various shunts have been designed to
use as peritoneovenous shunting [1,2], and radiological
insertion of the Denver shunt may be the most widely
used technique for nonsurgical PVS implantation in our
country. However, the mortality rate of PVS implanta-
tion has been reported to be rather high, and indications
are limited [3-6]. Possible contraindications for PVS
implantation include ascites that is infected, hemorrha-
gic, chylous, or with loculated malignant effusion,
advanced cardiac or renal failure, elevated serum biliru-
bin levels (6 mg/dL), portal hypertension, massive
pleural effusion, coagulation disorders, and poor perfor-
mance status (PS).
In addition, since a long subcutaneous tunnel should
be constructed in the implantation of a PVS, a PVS
once implanted in the subcutaneous tissue cannot be
readily modified, even when the system may get infected
or occluded [7], particularly in patients with severe ana-
sarca. Furthermore, postoperative incisional separation
of wound is considered to be main inappropriate reason
for PVS in patients with sever anasarca.
We applied an externalized peritoneovenous shunt
(EPVS) in 10 patients in whom conventional PVS was
considered to be inappropriate due to various reasons
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method. And EPVS was inserted to estimate the patients
whether they can tolerate subsequent PVS placement.
Patients and methods
We retrospectively reviewed 10 patients with refractory
malignant ascites who underwent EPVS placement
between January 2005 and December 2010. There were
32 cases of conventional PVS during the same period.
Inclusion criteria of EPVS were as follows: (1) malignant
ascites was confirmed cytologically or clinically, (2)
ascites was refractory to conservative nonsurgical thera-
pies, (3) there was no evidence of infection of the
ascites, (4) QOL was deteriorated because of the ascites,
and (5) conventional PVS was considered to inappropri-
ate because of severe anasarca, potential PVS dysfunc-
tion, history of PVS occlusion or poor PS.
Potential PVS dysfunction was defined as possible
shunt dysfunction due to particular characteristics of
ascites such as bloody or chylous. Poor PS was defined
as a life expectancy that was considered to be less than
a month. These patients did not have liver dysfunction,
portal hypertension, massive pleural effusion, or coagu-
lation disorders. Refractory ascites was diagnosed when
the ascites failed to respond to conservative therapy
(fluid restriction to 1000 mL/day, 100 mg/day of spiro-
nolactone, or 40 mg/day of furosemide for 4 weeks), or
when the patients had intolerance to these conservative
therapies because of azotemia [8-10].
We employed a PVS kit (Denver-PAK; Denver Bioma-
terials, Inc., Golden, CO, USA) in all patients. Proce-
dures were carried out under local anesthesia by
interventional radiologists. The abdominal catheter was
inserted into the Douglas cavity through the 16-F
sheath. Then the venous catheter was inserted into the
right or the left subclavian vein and was placed at the
lower portion of the superior vena cava through the 12-
F sheath. Ultrasound and X-ray fluoroscopy was used
for the guidance of the catheters insertion (Figure 1).
Technical success was defined as the creation of the
shunt and catheter insertions into both the abdominal
cavity and superior vena cava. Immediately after the
procedures, 500 mg of hydrocortisone sodium succinate
and 20 mg of furosemide were administered intrave-
nously to reduce acute biochemical reactions related to
the shunting and strain on hemodynamics. For the
patients with normal renal function (n = 8), 2 g/day of
cefazolin (CEZ) was given intravenously for 3 days. In
all patients (n = 10), 3 μg/kg/min of catecholamines was
administered in order to maintain more than 1000 ml/
day of urine volume for 3 days. In the patients who had
less than 10 × 10
3 cells/mm
3 of blood platelets (n = 2),
100 mg/day of gabexate was administered for 7 days.
Central venous pressure was continuously monitored in
order to minimize fluid overload, and chest X-ray pic-
tures were checked in order to detect pulmonary edema.
Patient characteristics, technical success, efficacy, the
duration of EPVS placement, adverse events, and out-
come were retrospectively evaluated. Technical success
was defined as the creation of the shunt with catheter
insertions into both the abdominal cavity and the super-
ior vena cava. We also evaluated hematological para-
meters, abdominal girth, and diuresis before and after
EPVS placement. Improvement of anasarca was evalu-
ated as a decrease of abdominal girth.
We asked patients about subjective symptoms before
and after the EPVS procedures. Clinical efficacy of the
EPVS was evaluated by the change in subjective symp-
toms. Each EPVS procedure was classified into 2 groups:
effective, in which the duration of the improvement of at
least one of 3 subjective symptoms from the ascites
(abdominal distention, anorexia, and nausea/vomiting)
was 7 days or more; ineffective, in which there was no sub-
jective improvement, or the duration of symptom
improvement was less than 7 days. If EPVS was exchanged
to PVS within 7 days, EPVS was judged effective when at
least one of 3 subjective symptoms from the ascites was
improved before EPVS was exchanged to PVS.
PS was evaluated by the Eastern Cooperative Oncol-
ogy Group Performance Status (ECOGPS) [11]. Adverse
events (AEs) were categorized according to the clinical
practice guidelines of the Society of Interventional Radi-
ology. Major AEs were defined as those necessitating an
increased level of care, major therapy, or prolonged hos-
pitalization, and those resulting in permanent sequelae
or death. Minor AEs were defined as those necessitating
nominal therapy or observation only [12].
When conventional PVS therapy was followed by
EPVS implantation, a subcutaneous tunnel was created
Figure 1 A photograph of EPVS placement in a patient with
chondrosarcoma (Patient No. 10). The venous and peritoneal
parts of the Denver shunt catheter have been inserted, and the
catheter is on the skin. (The patient provided consent for the
photograph to be published.)
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abdominal catheter was exchanged by injecting saline
solution into the abdominal cavity in order to prevent
damage to the adjacent organs. The venous side catheter
was also exchanged using a guidewire.
Informed consent was obtained from each patient
before EPVS implantation was performed, and the insti-
tutional review board of our institution approved this
technique. This study was conducted in accordance with
the amended Helsinki Declaration.
Results
Characteristics of the 10 patients (3 men and 7 women;
mean (SD) age, 52 (13) years; range, 22-69) are listed in
Table 1. The reasons for the use of EPVS placement
instead of a conventional PVS were poor PS in 4
patients, severe anasarca in 4 patients, potential PVS
dysfunction in 4 patients, and a history of PVS occlusion
in 2 patients (with overlap). The patency period of initial
PVS in the patients (No. 4 and No. 8) who had a history
of PVS occlusion was 192 and 69 days. Subsequent PVS
placement might be possible because the function of
initial PVS did not have any problems for a long period.
However, EPVS placement was performed because char-
acteristics of ascites were bloody and chylous.
Technical success was obtained in all patients without
any major AEs that were associated with the procedure.
EPVS placement provided clinical efficacy in 8 (80%)
patients, and the procedure was effective for abdominal
distention in 8 patients, anorexia in 5 patients, and nau-
sea/vomiting in 4 patients (with overlap). The largest
abdominal girth was resolved in all patients. However,
given the low sample size, we were unable to perform a
statistical analysis to test for a correlation between
hematological parameters, abdominal girth, and diuresis,
before or after EPVS placement (Table 2).
The median duration of EPVS placement was 10.4
days (range, 2-28 days). The EPVS was exchanged to
conventional PVS sequentially in 6 patients (60%), since
the initial EPVS placements resulted in improvement of
subjective symptoms without major AEs, and the
patients’ life expectancies were suspected to be more
than a month. In these 6 patients, the EPVS system was
removed and exchanged to conventional PVS on the
same day. There were no cases of EPVS and PVS dys-
function on the follow-up period. Patency period of
EPVS and PVS were 10.4 days (range 2-28 days) and
106 days (9-196 days).
The median survival duration was 74.0 days (range, 2-
200 days). The survival durations of the patients with
Table 1 Patient characteristics for 10 patients who received EPVS
No. age sex primary disease nature of
ascites
PS indication for EPVS EPVS
duration,
days
survival
duration, days
outcome AEs
1 22 F synovial sarcoma serous 3 poor PS 6 6 not
effective
renal failure**
2 64 M mesothelioma serous 1 potential PVS
dysfunction
3 133 effective* none
3 46 M lymphoma serous 4 anasarca, poor PS 14 23 effective* pulmonary
edema**, diarrhea
4 62 F ovary cancer bloody 1 history of PVS
occlusion
4 200 effective* none
5 49 F colon cancer bloody 1 anasarca, potential PVS
dysfunction
4 77 effective* none
6 57 F mesothelioma serous 1 potential PVS
dysfunction
16 133 effective* none
7 56 F breast cancer chylous 1 potential PVS
dysfunction
3 114 effective* none
8 48 F lung cancer chylous 1 anasarca, history of
PVS occlusion
28 28 effective diarrhea, anemia
9 50 F cholangiocarcinoma chylous 4 anasarca, poor PS 24 24 effective diarrhea
10 69 M chondrosarcoma serous 4 poor PS 2 2 not
effective
renal failure**
median 52.3 10.4 74.0
The EPVS system was removed and exchanged to conventional PVS on the same day.
PS: Eastern Cooperative Oncology Group Performance Status.
EPVS: externalized peritoneovenous shunt.
PVS: peritoneovenous shunt, AEs: adverse events.
*: EPVS was exchanged to conventional PVS.
**: major adverse event.
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(range, 2-24 days).
Three patients (30%) had major AEs. Acute death
occurred within 7 days after EPVS placement in 2
patients (No. 1 and No.10) because of renal failure
which had been occurred by hypovolemia since preo-
perative days. Before EPVS placement, these patients
had renal dysfunction and low serum albumin levels. As
one patient (No. 3) experienced pulmonary edema just
after the EPVS placement, we clumped the catheter to
avoid hyperperfusion on the 3
rd postoperative day until
the pulmonary edema was resolved on the 5
th post-
operative day.
Minor AEs were observed at 30% (diarrhea in three
patients and anemia in one patient) and were resolved
conservatively.
Discussion
Our results suggest that EPVS placement for refractory
ascites is effective and can be adopted even for patients
who were not suitable for a conventional PVS implanta-
tion because of anasarca, poor PS, potential PVS dys-
function, or history of PVS occlusion. However, EPVS
placement resulted in a 20% procedure-related early
death. We suggest that careful assessment of the proce-
dure-related risks and close monitoring after EPVS
implantation are essential.
Malignant ascites in patients with advanced cancer is
often resistant to treatment. Troublesome symptoms from
ascites result in progressive deterioration of the patients’
QOL. Diuretics and paracentesis have been traditionally
employed to relieve the symptoms associated with ascites.
However, their use has been inconsistent among physi-
cians. It is sometimes difficult for patients or caregivers to
bring patients to the place where paracentesis is per-
formed. Repeated paracentesis requires frequent trips to
the hospital with risks of hypovolemia, hypotension, and
hypoproteinemia from ascites removal [6].
Although paracentesis can provide immediate relief,
the effects may be temporary, and complications, such
as bleeding, hypotension, secondary peritonitis, and loss
of protein and electrolytes, may occur [13,14]. Since the
f i r s tr e p o r tb yL e V e e ne ta l .[ 1 ] ,t h eD e n v e rP V Sh a s
been considered as one of the most common procedures
used to treat intractable malignant ascites, in which
other conservative medical therapies may not be effec-
tive [1-7].
Although PVS is simple and an about 70% clinical
effectiveness is expected, AEs, such as pulmonary
edema, pulmonary arterial embolism, and disseminated
intravascular coagulation (DIC), following PVS implan-
tation may frequently occur. In addition, shunt replace-
ment (removal) is often warranted due to shunt
infection or occlusion of the system [3-7]. Efficacy of
PVS would not be superior to that of paracentesis in
short period, therefore PVS implantation has been con-
sidered to be a contraindication in patients with malig-
nant ascites due to gastrointestinal malignant tumors,
and a shunt should only be used when the life expec-
tancy of the patients expected to derive a benefit from it
is more than 2 or 3 months ([3-5,15]).
B i e l i g ke ta l .[ 7 ]r e p o r t e dt h a tp r e o p e r a t i v ei m p a i r e d
renal function was a predictive factor of poor prognosis
after PVS insertion. Thus, careful consideration should
be taken in deciding on placement in patients with
insufficient urine volume, who may be unable to tolerate
the rapid increase in plasma volume immediately after
PVS insertion [5,7]. In fact, in our study, early death
occurred within 7 days after EPVS placement in 2
patients because of progressive renal failure. Before
EPVS placement, these patients had renal dysfunction
and low serum albumin levels. After EPVS placement,
ascites volume was decreased in these patients, although
they had impaired production of sufficient urine volume.
A possible explanation is that the low colloid osmotic
pressure of these conditions may lead to extravascular
transudation of water, resulting in renal failure due to
hypovolemia [5,7,16,17].
Our EPVS procedure has some advantages over con-
ventional (PVS) implantation. Not only EPVS is place-
ment technically simpler, but EPVS may be less invasive
for patients. A subcutaneous long tunnel is not need for
EPVS. We can easily maintain the system, and the flow
c o n t r o li se a s i l yp e r f o r m e da ta n yt i m e .T h i si sav e r y
important advantage of EPVS placement, since PVS
insertion may result in rapid changes in circulatory
dynamics, as well as rapid introduction of various agents
present in ascites into the circulation. For example,
when severe complications, such as pulmonary edema
or dyspnea, occur, we can readily occlude the shunt
Table 2 Hematological parameters, abdominal girth, and
diuresis, before and after EPVS placement
Preoperative
Period
3-POD 7-POD 14-POD
Cr, mg/dL 1.1 (0.6) 1.2 (0.7) 1.1 (0.8) 1.1 (0.9)
BUN, mg/dL 21.2 (10.6) 22.6 (13.7) 23.5 (13.7) 27.8 (15.8)
Albumin, g/dL 2.3 (0.3) 2.4 (0.4) 2.6 (0.5) 2.5 (0.6)
PT, % 70.1 (13.8) 60.8 (12.5) 68.6 (13.10) 67.6 (10.4)
Platelets,
10
3 cells/mm
3
35.8 (9.1) 26.7 (10.6) 25.3 (8.7) 29.3 (6.8)
Largest
abdominal
girth, cm
87.5 (9.6) 84.1 (10.6) 81.7 (5.1) 80.2 (4.8)
Diuresis,
24 h, mL
978 (466) 1723 (560) 1612 (416) 1334 (506)
Data are presented as mean (SD).
POD: postoperative day.
PT: prothrombin time.
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the chamber is easily performed. Thus, we can educate
the patients and their family members on how to con-
trol the flow. It is easy to explain the mechanism of the
PVS to patients and their families. Besides device main-
tenance, replacement and removal of the EPVS system
are also far easier than conventional PVS [6,18]. We
suspect that an EPVS placement can also be a prepara-
tory step for standard conventional PVS implantation.
In our series, in six patients, EPVS has been successfully
exchanged to a conventional PVS system.
The development of a PVS that can be turned on or
off would be a useful development, even though this
w o u l dn o tr e a l l yg e ta r o u n dt h ea n a s a r c ap r o b l e m .I fa
flow control valve could be incorporated into the circuit
(like a ventriculoperitoneal shunt for hydrocephalus),
this might solve some of the problems that can occur
with PVS implantation.
There are a number of possible limitations with EPVS
implantation. First, there are no consistent preoperative
indicators associated with poor patient survival after EPVS
placement, and it is difficult to know which patients will
achieve a high rate of palliation with a low morbidity and
mortality rate [3-6]. In cases of anasarca, it may be ade-
quate to exchange EPVS so that abdominal distension will
resolve. However, in other cases, it is difficult to seize a
favorable occasion to convert from EPVS to conventional
PVS. In our small cohort, a conversion to PVS depends
upon the condition of the patients, and we could not but
have tentative period or factors to decide when EPVS is
exchanged to PVS. An improvement in nutritional status
can improve the chance of a successful conversion to PVS.
However, it is not easy to improve nutritional status in a
patient at the end of life. We suspect the success of the
conversion can occur if the major AEs are avoided after
EPVS placement because EPVS placement is a temporary
system that is used temporarily in place of conventional
PVS. Previous studies have emphasized meticulous post-
procedural management for 48 hours in order to detect
major AEs [4,19]. Therefore, we suspect that increased
attention should be given for more than 48 hours after the
procedure. Second, EPVS placement may have a higher
risk for system infection and migration, although we did
not have any such cases in our series. However, the dura-
tion of the EPVS placements in this study is considerably
short to define infection risks for any tunneled catheter,
such as that used for pleural effusion, dialysis, central
lines, etc. [6,18]. Third, there is an economical issue: when
patients were able to get the favorable clinical course asso-
ciated with EPVS placement, they had to pay for another
Denver shunt kit in order to convert the EPVS system to
PVS.
Additional limitations of the study include the follow-
ing: the study was retrospectively performed, there were
a small number of patients, and the follow-up period
was very short. No consensus on how to evaluate the
efficacy of PVS or EPVS has been established [20,21].
Our subjective procedure for determining the efficacy 7
days after EPVS insertion is controversial. Additionally,
if ascites was removed with the PVS implantation proce-
dure itself, it can palliate symptoms separately from an
effect of the EPVS. We evaluated the improvement of
anasarca as a decrease of abdominal girth, and there was
no weight data in all patients. No consensus on how to
evaluate anasarca in patients with malignant ascites.
Abdominal girth may not an appropriate index of ana-
sarca because abdominal girth may also represent
decrease of ascites after PVS insertion.
A previous study recommended measuring body
weight in order to evaluate PVS efficacy, but it may be
occasionally difficult to measure body weight in patients
at the end of life. In addition, patients with advanced
malignancies may deteriorate rapidly due to the primary
disease and other pathophysiologies that further con-
found evaluation. We attempted to minimize fluid over-
load. However, flow control is a regular and needed issue
for percutaneous shunts, and it is difficult to assess circu-
latory dynamics [10]. In future studies, we need to assem-
ble a larger cohort that we will follow over a longer term
in order to evaluate efficacy and complications.
Conclusion
In conclusion, EPVS placement may be an option
method for patients with malignant ascites, who may
not be appropriate for conventional PVS implantations.
Our preliminary experience encourages further studies
into the efficacy of EPVS placement.
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